Orchestra BioMed randomized 330 patients, above its 316-patient target, moving its main trial past planned enrollment. The report gives no treatment results, and commercial use still needs regulatory approval.
Passing the enrollment target moves the study closer to testing its main question with enough patients. That progress helps Orchestra BioMed, but the filing reports no treatment results, and commercial use still needs regulatory approval.
Medtronic is working with Orchestra BioMed on the trial and may help sell the therapy if regulators approve it. This update reports no treatment results or approval, so it does not show a change in Medtronic's business outlook.
Follow Orchestra BioMed Holdings, Inc. (OBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for OBIO